Magnitude of elevated iron stores and risk associated in steady state sickle cell anemia Congolese children: a cross sectional study

Jean-Robert Makulo 1*, Karen Efombola Itokua 2, Rosette Kevani Lepira 2, Gloire Mavinga Bundutidi 2, Michel Ntetani Aloni 2, René Makuala Ngiyulu 2, Jean Lambert Gini 2 and François Bompeka Lepira 1

Abstract

Background: The serum ferritin assay is recommended in Sickle Cell Anemia (SCA) patients receiving regular transfusions. According to several authors, elevated iron stores indicating iron chelation corresponds to hyperferritinemia ≥500 ng/ml, and becomes detectable after twenty blood transfusions. The objectives of the study were to determine the prevalence of elevated iron stores and identify associated risk factors in a case series of Steady state SCA Congolese children.

Material and methods: Serum ferritin was assayed in Steady state SCA children followed in 2 specialized hospitals in Kinshasa. Elevated iron stores was defined as serum ferritin level ≥500 ng/ml, and the associated risk factors were identified using univariate analysis.

Results: Seventy patients (median age 9 years, 56% boys, 53% receiving hydroxyurea) were selected in the study. Serum ferritin levels ranged from 24 to 2584 ng / ml with 21.4% of children having elevated iron stores. Mean levels of LDH, indirect bilirubin, plasma free Hb and CRP were similar between the 2 groups whereas history of polytransfusions (> 3 during the last year) was more frequent among patients with elevated iron stores (73% vs. 44%, \( p = 0.078 \)). Receiving > 3 transfusions in a year vs. 0 was the main risk factor associated with elevated iron stores \([OR 6.17 (95\% CI: 1.81–20.96)]\).

Conclusion: In SCA children, hyperferritinemia requiring iron chelation is most strongly related to blood transfusion. This situation concerned almost one in five children in present study; this shows the magnitude of the problem which is underestimated.

Keywords: Sickle cell anemia, Elevated iron stores, Polytransfusions, DR Congo

Introduction

Sickle cell anemia (SCA) is the most common genetic disease in populations of African descent [1]. According to African regions and tribes, the homozygous form affects 1 to 2% of live births, whereas the heterozygous form can affect 10 to 35% of individuals [2, 3]. The hyperhemolytic crisis, one of the most common complications of this disease, usually requires urgent transfusion therapy, which exposes to iron overload since each transfused red blood cell provides about 200 mg of iron [4].

The management of sickle cell disease guidelines (The National Heart Lung and Blood Institute) recommends monitoring and treatment of iron overload in any patient who is regularly transfused [5]. Serum ferritin is the most frequently used test to estimate iron overload [5]. In steady state, several studies show a significant correlation between total transfused units by simple top-up and serum ferritin [6]. For the World Health Organization (WHO), the risk of iron overload in patients over 5 years-of-age is elevated beyond 200 ng / ml [7]. However, organic lesions may occur at ferritin levels...
above 1000 ng/ml, and some authors recommend chelation as soon as ferritin levels exceed 500 ng/ml [8].

The Democratic Republic of the Congo (DRC) has the third highest population of SCA patients in the world after Nigeria and India. However, SCA is not yet really regarded as a healthcare priority, despite WHO resolution [9]. Children with SCA are known to have an increased risk of blood transfusion and iron overload, especially in areas with holoendemic malaria like the DRC. Previous studies have reported that transfusions because of severe anaemia have been necessary in children with SCA [10–13]. Despite these high prevalence, few studies focused on the assessment of iron homeostasis in steady state SCA children. The dosage of ferritin for SCA is not common practice in DRC and is only possible in a few major health institutions in the country, meaning that diagnosis of iron overload and its organ damage are underestimated and delayed. In our midst, Tshilolo et al. reported that 35% of homozygous sickle cell children had ferritin levels above 300 ng/ml [14]. However, the number of those who require iron chelation is unknown. The objectives of this study were to estimate the prevalence of elevated iron stores and to identify the associated risk factors in a population of SCA children followed in 2 hospitals in Kinshasa specialized in the management of Sickle cell disease.

Material and methods

The present study is a post-hoc analysis that uses the results of an oxidative stress study in homozygous SCA Congolese children whose methodological procedures have been detailed in previous publications [15, 16]. Briefly, SCA children between 2 and 18 years-of-age consecutively followed in two hospitals in the country's capital Kinshasa, namely the Centre Médical Monkole and the Saint-Crispin Medical were selected for the period from 15 June, 2014 to 30 August, 2014. These health facilities are specialized in the care management of SCA. Only steady state children (exclusion of SCA children who were transfused, hospitalized and had a major vaso-occlusive crisis within the last 2 months before the study) had been selected. Children with a history of liver disease or chronic alcoholism were excluded.

Serum ferritin (ng/ml) was assayed by the enzyme immunoassay using a Mini vida® device (BioMérieux, France). The blood count, total and direct bilirubin, assay of C reactive protein (CRP), lactate dehydrogenase (LDH) and serum iron were performed using a Cobas C111® device (Roche, Switzerland). Plasma free hemoglobin (Hb) was assayed spectrophotometrically using a Genesys 20® device (Thermo Fisher Scientific, USA). In the present study, elevated iron stores (hyperferritinemia) was defined as ≥500 ng/ml [8]. The normal rates of serum iron were defined as values between 10 and 30 μmol/l.

Results

A total of 70 SCA children (56% boys, 53% receiving hydroxyurea = HU) were selected. Their median age was 9 years with an interquartile range (IQR) of 6 to 13 years. In the past 12 months, half of children (50%) had received more than 3 transfusions, 37% had received 1–3 transfusions, and 13% had not been transfused (Table 1).

Ferritin levels ranged from 24 to 2584 ng/ml. Serum ferritin levels ≥500 ng/ml and ≥1000 ng/ml were found in 15 children (21.4%) and 4 children (5.7%), respectively. Among children with serum ferritin levels ≥500 ng/ml, 93.3% had normal iron level while 29 and 14% of them had CRP level > 6 mg/l and CRP > 12 mg/l, respectively. Polytransfusion (> 3 in the last 12 months) was associated with hyperferritinemia ≥500 ng/l; high CRP levels appeared to be associated with hyperferritinemia, but the difference was not statistically significant (Table 2).

Figure 1 shows that in the whole group, serum ferritin levels increased proportionally with the number of blood transfusions received during the last year; median values of serum ferritin levels were 125 ng/ml in the group 1 (IQR: 99–185 ng/ml), 222 ng/ml in the group 2 (IQR: 102–453 ng/ml), and 301 ng/ml in the group 3 (IQR: 123–747 ng/ml) (p = 0.010).

Receiving 1–3 transfusions in a year vs. 0 [OR 3.08 (95% CI: 1.06–8.97)] and >3 transfusions in a year vs. 0 [OR 6.17 (95% CI: 1.81–20.96)] were the only two risk factors of elevated iron stores retained in univariate analysis.

Statistical analysis

Comparisons of groups were analyzed using the Chi Square test or Fisher Exact test for the categorical variables, and the Student or Mann Whitney tests for the numerical variables according to whether the distribution of the variables was Gaussian or not Gaussian. The risk factors associated with elevated iron stores were investigated in univariate analysis and considered significant at the 5% level of significance (p < 0.05). We performed logistic regression analysis which evaluated the following variables: lack of hydroxyurea, inflammatory status (CRP > 6 mg/l and CRP > 12 mg/l), hemolytic status (LDH > median value and plasma free Hb > median value), age > 5 years and receiving transfusions vs 0 transfusion in a year.

Ethical approval

Ethical approval for the study was granted by the institutional review boards of the Centre Médical Monkole (006 CEFA-MONKOLE/2014) in line with the principles of the Declaration of Helsinki, second revision. The aim and study procedures were explained to the parents or legal guardians and they provided written consent before any of the subjects where included.
Discussion

The present study showed that approximately one in five homozygous SCA children had hyperferritinemia level requiring iron chelation. Multiple blood transfusions emerged as the only determinant of elevated iron stores. In SCA, elevated serum ferritin levels may reflect inflammatory syndrome, hemolysis or transfusion therapy [17]. In the present study, only patients who were in steady state over the last 2 months were selected suggesting a likely reduced impact of inflammation and inflammation.

| Table 1 | Clinical and biological profile of the study population |
| --- | --- |
| | Whole group | male | female | p |
| Age, years | 9(6–13.3) | 10(7–14) | 9(5–12) | 0.789 |
| Transfusions > 3/year | 35(50) | 23(59) | 12(39) | 0.189 |
| 1–3/year | 26(37) | 13(33) | 13(42) |
| 0/year | 9(13) | 3(8) | 6(19) |
| WBC/mm³ | 11.618 ± 4.621 | 11.339 ± 4.114 | 12.011 ± 5.311 | 0.568 |
| Platelets ×10³/mm³ | 380.727 ± 154.522 | 364.359 ± 132.846 | 401.884 ± 184.553 | 0.344 |
| Reticulocytes, % | 12.0 (8.5–17.6) | 11.0 (8.5–18.0) | 13.0 (8.0–17.8) | 0.799 |
| CRP, mg/l | 3.43 (2.01–5.07) | 3.44 (2.52–5.99) | 3.36 (1.88–5.01) | 0.891 |
| Total Bilirubin, mg/dl | 1.9 (1.5–3.5) | 2.5 (1.6–4.2) | 1.9 (1.5–3.5) | 0.841 |
| Indirect Bilirubin, mg/dl | 1.9 (0.9–3.5) | 1.9 (1.0–3.6) | 1.3 (0.9–3.2) | 0.823 |
| Direct Bilirubin, mg/dl | 0.5 (0.4–0.7) | 0.6 (0.4–0.7) | 0.5 (0.4–0.7) | 0.680 |
| LDH, UI/l | 544(400–771) | 550(424–795) | 516(375–686) | 1.000 |
| Serum iron, μmol/l | 16.2 (13.2–19.2) | 16.2 (13.2–19.0) | 16.3 (11.7–20.3) | 0.941 |
| Serum ferritin, ng/ml | 209 (106–453) | 184 (97–440) | 213 (106–519) | 0.891 |
| Free plasma Hb, mg/l | 168 (116–267) | 168 (110–282) | 160 (120–244) | 0.950 |

Record values are expressed as absolute frequency (%), mean ± standard deviation or median (IQR 25–75)

Abbreviations: WBC white blood cells, CRP C reactive protein, LDH Lactate dehydrogenase, Hb hemoglobin

| Table 2 | Serum Ferritin level-based characteristics of SCA children |
| --- | --- |
| Serum ferritin | < 500 ng/ml (n = 55) | ≥ 500 ng/ml (n = 15) | p |
| male, % | 31(57) | 8(33) | 0.976* |
| Age < 5 years, % | 10(18) | 5(33) | 0.286* |
| HU, % | 26(48) | 10(67) | 0.247* |
| Major VOC ≥ 2/an, % | 6(11) | 3(20) | 0.391* |
| Transfusions > 3/year, % | 24(44) | 11(73) | 0.078* |
| Hct, % | 22.4 (20.7–24.8) | 22.4 (19.0–28.1) | 0.903 |
| Platelets ×10³/mm³ | 387 (293–472) | 288 (172–427) | 0.239 |
| WBC, ×10³/μls/mm³ | 11.5 (8.4–14.6) | 9.9 (7.2–17.6) | 0.951 |
| Reticulocytes, % | 11.9 (8.0–17.0) | 13.0 (9.5–23.3) | 0.964 |
| CRP, mg/l | 3.4 (2.0–4.8) | 3.8 (2.3–8.5) | 0.764 |
| CRP ≥ 6 mg/l, % | 7(13) | 4(29) | 0.233* |
| CRP ≥ 12 mg/l, % | 3(5) | 2(13) | 0.290* |
| Indirect Bilirubin, mg/dl | 1.9 (1.0–3.6) | 1.3 (0.9–2.0) | 0.547 |
| LDH, UI/l | 568 (424–771) | 488 (320–782) | 0.559 |
| Free plasma Hb, mg/l | 183 (123–282) | 130 (107–205) | 0.479 |
| Serum iron, μmol/l | 16.1 (12.4–19.5) | 16.8 (14.9–19.9) | 0.849 |

Record values expressed as frequency or median (IQR 25–75)

Abbreviations: Hct: hematocrit, WH: white blood cells, CRP: C reactive protein, LDH: Lactate dehydrogenase, Hb: hemoglobin, HU: hydroxyurea, VOC: vaso-occlusive crisis

*Fisher Exact test
hemolysis on measured ferritin levels. Furthermore, many studies have reported that increases in serum ferritin levels induced by inflammatory and hemolysis states are usually moderate (<500 ng/ml) [17, 18]. Higher rates of serum ferritin levels can be seen in alcoholism and some liver diseases not present in our case series [19].

According to several authors, iron overload becomes detectable after 20 blood transfusions [20]. Almost half of our patients and / or their tutors were unable to accurately recall the number of transfusions received since birth, so this assessment was not possible. However, our results indicate that, regardless of the number of blood transfusions received in previous years, children with more than three blood transfusions during the year, experienced elevated iron stores. In a previous Congolese study, Tshilolo et al. showed that the average blood transfusion requirement was 0.4 units per patient-year in Congolese SCA patients [11]. However, our finding need to be strengthen by taking into account of other confounders such as the exact volume of blood received by each patient, the nature of transfused blood (whole blood, red blood cell, single transfusions or erythrapheresis), initial iron status and co-morbidities. Unfortunately, these factors were not available in this post-hoc analysis.

The cumulative and deleterious effects of blood transfusions on iron overload rely upon iron metabolism. Indeed, iron has been reported to lack a physiologic system of elimination exposing it to cumulate in case of increased intake. Thus, during transfusion of red blood cell, nearly 200 mg of iron reach the body; however, every day barely 1 mg of iron is eliminated through the skin and intestinal epithelial: iron is thus eliminated very slowly [4, 20, 21]. The complete saturation of transferrin and ferritin facilitates the binding of iron to other circulating molecules, the basis for the accumulation of reactive iron complexes within parenchymal cells [21]. During the transfer of electrons between iron molecules of different valences (Fe3+ and Fe2+), extremely reactive free radicals are formed with subsequent oxidative damage of tissues and organs [21, 22].

The frequency of the elevated iron stores ranges from 22 to 41.5% in African studies [11, 14, 23–25]. These differences in the relative proportions of elevated iron stores between these studies presumably arise from differences in the definition of hyperferritinemia, age of the study population, environmental, immunologic and genetic factors that influence iron status in sickle cell population. These situations strongly suggest that more research in African countries would provide valuable insights into the pathogenesis of iron overload as reported in a recent Egyptian cohort [26].

Failure to perform liver biopsy to assess iron overload constitutes a limitation of the present study. In the absence of this invasive technique, imaging techniques such as magnetic resonance and Superconducting Quantum Interference Device (SQUID) have been reported to provide a good correlation between iron tissue concentrations and potential organic damage [27]. However, as a general rule, the serum ferritin concentration assay offers an interesting alternative. Indeed, several studies have shown a linear correlation between serum ferritin levels and total body iron load, based on the results of the assessment of hepatic iron concentration by biopsy analysis [5, 7, 8].

Considering the results of this study, local physicians should be sensitized to avoid iterative transfusions by
respecting the indications for blood transfusion in SCA, to perform serum ferritin test, in particular from more than 3 blood transfusions during the year. Indications of iron chelation therapy must be known and systematized to prevent comorbidities associated with iron overload.

**Conclusion**

In SCA children, hyperferritinemia requiring iron chelation is most strongly related to blood transfusion. This situation concerned almost one in five children in present study; this shows the magnitude of the problem which is underestimated.

**Abbreviations**

CRP: C reactive protein; Hb: Hemoglobin; Hct: Hematocrit; HU: Hydroxyurea; LDH: Lactate dehydrogenase; SCA: Sickle cell anemia; VOC: Vaso-occlusive crisis; WBC: White blood cell

**Acknowledgements**

We are grateful to the laboratory technicians of the Centre Hospitalier Mère et Enfants de Monkole, Centre Hospitalier-Saint-Crispin and the School of Public Health of the University of Kinshasa for the analyses of the samples.

**Funding**

This work received no financial assistance from any funding agency in the public, commercial or non-profit sectors.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

KEI participated in the design, data collection and writing of the manuscript. RKL, MNA, RMN and JLG participated in the design and writing of the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Ethical approval for the study was granted by the institutional review boards of the Centre Médical Monkole (006 CEFA-MONKOLE/2014) in line with the principles of the Declaration of Helsinki, second revision. The aim and study procedures were explained to the parents or legal guardians and they provided written consent before any of the subjects where included.

**Consent for publication**

not applicable.

**Competing interests**

The authors have no conflicts of interest to disclose.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Division of Nephrology, Nephrology Unit, Department of Internal Medicine, University Hospital of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa XIPPO.BOX 123Democratic Republic of Congo. 2Division of Hemato-Oncology and Nephrology, Department of Paediatric, University Hospital of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of Congo.

**References**

1. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle cell disease: Basic principles and clinical practice. Raven Press 1994; 311–326.
2. Tshilolo L, Aissi LM, Lukusa D. Neonatal screening for sickle cell anemia in the DR Congo experience from a pioneer project on 31 204 newborns. J Clin Pathol. 2009;62:35–8.
3. Dennis-Antwi JA, Dyson S, Ohene-Frempong K. Healthcare provision for sickle cell disease: challenges for the African context. Diversity in Health and Social Care. 2008;5:241–54.
4. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986–95.
5. National Institute of Health: National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources: The management of sickle cell disease. NHI Publications 2002: 02–2117.
6. Stanley HM, Friedman DF, Webb J, Kwaïkowski JL. Transfusional iron overload in a cohort of children with sickle cell disease: impact of magnetic resonance imaging, transfusion method, and chelation. Pediatr Blood Cancer. 2016;63(8):1414–8.
7. OMS. Concentrations sériques de ferritine permettant d’évaluer le statut et les carences en fer dans les populations. Système d’informations nutritionnelles sur les vitamines et les minéraux. Genève. OMS, 2011.
8. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38:30–6.
9. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality and interventions. PLoS Med. 2013;10(7):e1001484.
10. Aloni MN, Tshimanga BK, Ekulu PM, Ehungu JL, Ngiru Yu RM. Malaria, clinical features and acute crisis in children suffering from sickle cell disease in resource-limited settings: a retrospective description of 90 cases. Pathog Glob Health. 2013;107(6):198–201.
11. Tshilolo LM, Mukendi RK, Wembonyama SO. Blood transfusion rate in Congolese patients with sickle cell anemia. Indian J Pediatr. 2007;74:735–8.
12. Aloni MN, Nkeye L. Challenge of managing sickle cell disease in a pediatric population living in Kinshasa, Democratic Republic of Congo: a sickle cell center experience. Hemoglobin. 2014;38(3):196–200.
13. Kadima BT, Gini Ehungu JL, Ngiru Yu RM, Ekulu PM, Aloni MN. High rate of sickle cell anemia in sub-Saharan Africa underlines the need to screen all children with severe anemia for the disease. Acta Paediatr. 2015;104(12):1269–73.
14. Tshilolo L, Ngode ZM, Ngiru Yu R, Kayembe ND. Iron status in 72 Congolese patients with sickle cell anemia. Med Sante Trop. 2016;26(1):83–7.
15. Itokua EK, Makulo JR, Lepira FA, Aloni MN, Ekulu PM, Sumali EK, et al. Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with sickle cell anemia. BMC Nephrol. 2016;17:178.
16. Itokua EK, Ngiru Yu R, Makulo JR, Lepira FA, Aloni MN, Sadiki H, et al. GPs and Cu-Zn SOD activities in homozygous sickle cell Anemia: the primary role of hydroxyurea. Innov Res Health Sci Biotechnol. 2016;1(3):85–91.
17. Darnade R, Cacoub P. Les hyperferriémies. Ann Med Interne. 2000;151(2):169–77.
18. Weiss G. Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol. 2005;18:183–201.
19. Chapman R, Morgan R, Lautlitch M, Hoffbrand A, Sherlock S. Hepatic iron store and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci. 1982;27.099–19.
20. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):293–52.
21. Conrad UE, Umbreil JN, Moore EG. Iron absorption and transport. Am J Nutr. 1999;318:213–29.
22. Lafond Jl AJ. Iron metabolism. Rev Prat. 2000;50:945–9.
23. Akinbami AA, Dosunmu AO, Adeidan AA, Oshinaike OO, Osunkalu VO, Ajibola SO. Serum ferritin levels in adults with sickle cell disease in Lagos, Nigeria. J Blood Med. 2013;4:55–63.
24. Tayou Tagny CT, Oluome ME, Chetcha B, Mbanya D. Serum ferritin levels in 41 multiple-transfused sickle cell patients at the Yaounde central hospital, Cameroon, Africa: a pilot study. Int J Hem Res. 2015;1(1):24–6.
25. Hafisia R, Belahhal F, Ben Salah N, Goudier E, Elborji W. Iron overload in sickle cell anemia: a study of 94 patients. Tunis Med. 2011;89(6):548–52.

**Received:** 28 July 2017 **Accepted:** 9 January 2019
**Published online:** 08 February 2019
26. Abdel Rahman HA, Abou-Elew HH, El-Shorbagy RM, Fawzy R, Youssry I. Influence of iron regulating genes mutations on iron status in Egyptian patients with sickle cell disease. Ann Clin Lab Sci. 2014;44(3):304–9.

27. Gandon Y, Ollivé D, Guyader D, Aubé C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357–62.